Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception
Open Access
- 25 August 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (8), 2055-2061
- https://doi.org/10.1182/blood-2011-03-345678
Abstract
Current guidelines discourage combined oral contraceptive (COC) use in women with hereditary thrombophilic defects. However, qualifying all hereditary thrombophilic defects as similarly strong risk factors might be questioned. Recent studies indicate the risk of venous thromboembolism (VTE) of a factor V Leiden mutation as considerably lower than a deficiency of protein C, protein S, or antithrombin. In a retrospective family cohort, the VTE risk during COC use and pregnancy (including postpartum) was assessed in 798 female relatives with or without a heterozygous, double heterozygous, or homozygous factor V Leiden or prothrombin G20210A mutation. Overall, absolute VTE risk in women with no, single, or combined defects was 0.13 (95% confidence interval 0.08-0.21), 0.35 (0.22-0.53), and 0.94 (0.47-1.67) per 100 person-years, while these were 0.19 (0.07-0.41), 0.49 (0.18-1.07), and 0.86 (0.10-3.11) during COC use, and 0.73 (0.30-1.51), 1.97 (0.94-3.63), and 7.65 (3.08-15.76) during pregnancy. COC use and pregnancy were independent risk factors for VTE, with highest risk during pregnancy postpartum, as demonstrated by adjusted hazard ratios of 16.0 (8.0-32.2) versus 2.2 (1.1-4.0) during COC use. Rather than strictly contraindicating COC use, we advocate that detailed counseling on all contraceptive options, including COCs, addressing the associated risks of both VTE and unintended pregnancy, enabling these women to make an informed choice.Keywords
This publication has 30 references indexed in Scilit:
- State-of-the-art of non-hormonal methods of contraception: I. Mechanical barrier contraceptionThe European Journal of Contraception & Reproductive Health Care, 2010
- Efficacy of contraceptive methods: A review of the literatureThe European Journal of Contraception & Reproductive Health Care, 2010
- The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210AJournal of Thrombosis and Haemostasis, 2007
- High risk of pregnancy‐related venous thromboembolism in women with multiple thrombophilic defectsBritish Journal of Haematology, 2007
- Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosisJournal of Thrombosis and Haemostasis, 2004
- Familial thrombophilia and lifetime risk of venous thrombosisJournal of Thrombosis and Haemostasis, 2004
- Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism?The European Journal of Contraception & Reproductive Health Care, 2000
- Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertaintiesJournal of Internal Medicine, 1995
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994